Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (9090)	3/23/2002 7:51:41 PM
From: axial	Read Replies (1) \| Respond to of 14101

Hi, Wolf - "Its been quite a journey watching all the vitriol when the truth is she's one of the bigger reasons I invested and held." I wish I had met REK, as you have. I've seen her once, on the recent ROB TV interview, but that experience lacks the information one gets from a personal encounter. For most of us, the question of her nature has to be resolved by other data, specifically, performance. With no intent to detract from your personal observations (which have invariably been cautious and moderate) I would restate your words for those of us who must judge on other criteria: Its been quite a journey watching all the vitriol when the truth is... the sum of her known* accomplishments far exceeds the possible number of failures.* Talkinitup posted a nice little summary on SH: "1. took a drug from concept to market with no partner taking a percentage 2. within weeks of getting FDA approval with the safest drug on the market for OA 3. within weeks of signing JnJ (rated best consumer products marketing company in the world) 4. about to see the results of a Phase III AIDS drug for which they will have the complete rights to. With a Phase II that was so amazing, PIII has a close to certain chance of being positive. The question is how much. 5. Recovered from a drop in manufacturer by building a complete manufacturing facility within 1.5 years. To which I would add: (1) Overcoming a legacy of regulatory obstinacy on unconventional drugs and therapies (for which legacy, evidence has been produced). Working around HC's roadblock on WF10. (2) From (5) above - Working cooperatively with a number of parties to achieve the result with not ONE Form 483 on the Pre-Approval Inspection. From Bluejay's post... "We've seen a lot of complaints in the past that RK runs a one-woman show. Here's a little proof that that's not the case. The plant is Ruth Huttman's baby. I've seen many companies require a re-inspection. Dimethaid did it first time. They had no manufacturing experience as a company and were able to buy a plant, staff it, establish procedures, successfully ramp up production, and now obtain approval from the toughest regulatory body in the world. All with hardly a hiccup that we know of." Message 17074221 *(3) Working through possible* anti-competitive practices and corruption, and actions which have the appearance of political interference. Talkinitup also posted... "Have there been mistakes? Yes. However the good things far outweigh the bad. continuing to blame management for HC and the UK market differences will not help you in any way. As others posted here earlier, Celebrex and Vioxx had a VERY difficult time in the UK and still have a much smaller penetration there than the US." ____________________________________________________ For the longs, it has been a difficult road; simply on the basis of vindicating their faith, victory will be sweet. Perhaps it is too early to be listing accomplishments, but it is well to remember, on an arduous journey, just how far you have come. A new pharma, with unconventional drugs: nobody would have expected it to be easy, or error-free. But it has been harder, far more difficult than anticipated. One of the questions that faces many DMX investors is...what's next? If the price jumps, do I sell or stay? "Over the next few months, there is going to have to be a tremendous change in the way DMX handles, and disseminates news. The company is going to need a good strategy, strong partners - and sustainable share price. To me, these things mean that the company is going to have to change quickly. Can REK and the board make these changes? Can she silence the critics with a dazzling display of savvy moves? Can she do "the Cinderella thing" ?" Message 17096992 Based on the evidence from the past, the answer is YES**. Regards (and thanks to Talkinitup) Jim